Insulin regulates hepatic triglyceride secretion and lipid content via signaling in the brain

Diabetes

Volumn 65, Issue 6, 2016, Pages 1511-1520

  Scherer, Thomas ^a,b   Lindtner, Claudia ^a   O'Hare, James ^a   Hackl, Martina ^b   Zielinski, Elizabeth ^a   Freudenthaler, Angelika ^b   Baumgartner Parzer, Sabina ^b   Tödter, Klaus ^c   Heeren, Joerg ^c   Krššák, Martin ^b   Scheja, Ludger ^c   Fürnsinn, Clemens ^b   Buettner, Christoph ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; GLYCEROL; INSULIN; INSULIN RECEPTOR; MESSENGER RNA; TATA BINDING PROTEIN; TRIACYLGLYCEROL; TYLOXAPOL; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CENTRAL NERVOUS SYSTEM; FATTY ACID BLOOD LEVEL; FATTY LIVER; GENE EXPRESSION; GLUCOSE BRAIN LEVEL; GLYCEROL BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; LIVER; MALE; MUSCLE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS); SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; FATTY LIVER; INSULIN; LIPOPROTEINS, VLDL; LIVER; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 84964352862     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1552     Document Type: Article

References (50)

1. Kwon YM, Oh SW, Hwang SS, Lee C, Kwon H, Chung GE. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol 2012;107:1852-1858
2. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014;146:726-735
3. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351
4. Grefhorst A, Hoekstra J, Derks TG, et al. Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production. Am J Physiol Gastrointest Liver Physiol 2005;289:G592-G598
5. Schmid AI, Szendroedi J, Chmelik M, Krssák M, Moser E, Roden M. Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes. Diabetes Care 2011;34:448-453
6. Szendroedi J, Chmelik M, Schmid AI, et al. Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatology 2009;50:1079-1086
7. 31P MRS saturation transfer at 7 T for measurement of ATP metabolism in the liver: reproducibility and initial clinical application in patients with non-alcoholic fatty liver disease. Eur Radiol 2014;24:1602-1609
8. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999;282:1659-1664
9. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011;14:804-810
10. Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 2015;21:739-746
11. Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2012;5:199-207
12. Raabe M, Véniant MM, Sullivan MA, et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest 1999;103:1287-1298
13. Fabbrini E, Tiemann Luecking C, Love-Gregory L, et al. Physiological mechanisms of weight gain-induced steatosis in people with obesity. Gastroenterology 2016;150:79-81.e2
14. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008;134:424-431
15. Malmström R, Packard CJ, Watson TD, et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 1997;17:1454-1464
16. Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 2007;104:12587-12594
17. Anderwald C, Bernroider E, Krssak M, et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 2002;51:3025-3032
18. Gancheva S, Koliaki C, Bierwagen A, et al. Effects of intranasal insulin on hepatic fat accumulation and energy metabolism in humans. Diabetes 2015;64:1966-1975
19. Sparks JD, Sparks CE. Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. J Biol Chem 1990;265:8854-8862
20. Sparks JD, Phung TL, Bolognino M, Sparks CE. Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Biochem J 1996;313:567-574
21. Kamagate A, Qu S, Perdomo G, et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 2008;118:2347-2364
22. Wu K, Cappel D, Martinez M, Stafford JM. Impaired-inactivation of FoxO1 contributes to glucose-mediated increases in serum very low-density lipoprotein. Endocrinology 2010;151:3566-3576
23. Malmström R, Packard CJ, Caslake M, et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997;40:454-462
24. Bruinstroop E, Pei L, Ackermans MT, et al. Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system. Diabetes 2012;61:1043-1050
25. Stafford JM, Yu F, Printz R, Hasty AH, Swift LL, Niswender KD. Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion. Diabetes 2008;57:1482-1490
26. van den Hoek AM, Voshol PJ, Karnekamp BN, et al. Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. Diabetes 2004;53:2529-2534
27. Lam TK, Gutierrez-Juarez R, Pocai A, et al. Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins. Nat Med 2007;13:171-180
28. Scherer T, O'Hare J, Diggs-Andrews K, et al. Brain insulin controls adipose tissue lipolysis and lipogenesis. Cell Metab 2011;13:183-194
29. Koch L, Wunderlich FT, Seibler J, et al. Central insulin action regulates peripheral glucose and fat metabolism in mice. J Clin Invest 2008;118:2132-2147
30. Scheja L, Toedter K, Mohr R, et al. Liver TAG transiently decreases while PL n-3 and n-6 fatty acids are persistently elevated in insulin resistant mice. Lipids 2008;43:1039-1051
31. Lai YL, Smith PM, Lamm WJ, Hildebrandt J. Sampling and analysis of cerebrospinal fluid for chronic studies in awake rats. J Appl Physiol 1983;54:1754-1757
32. Hu SH, Jiang T, Yang SS, Yang Y. Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes. Exp Clin Endocrinol Diabetes 2013;121:220-224
33. Cashion MF, Banks WA, Kastin AJ. Sequestration of centrally administered insulin by the brain: effects of starvation, aluminum, and TNF-alpha. Horm Behav 1996;30:280-286
34. Stein LJ, Dorsa DM, Baskin DG, et al. Immunoreactive insulin levels are elevated in the cerebrospinal fluid of genetically obese Zucker rats. Endocrinology 1983;113:2299-2301
35. Schotz MC, Scanu A, Page IH. Effect of triton on lipoprotein lipase of rat plasma. Am J Physiol 1957;188:399-402
36. Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 2002;8:1376-1382
37. Muzumdar RH, Ma X, Fishman S, et al. Central and opposing effects of IGF-I and IGF-binding protein-3 on systemic insulin action. Diabetes 2006;55:2788-2796
38. Brüning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000;289:2122-2125
39. Tschritter O, Preissl H, Hennige AM, et al. The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci U S A 2006;103:12103-12108
40. Scherer T, Lindtner C, Zielinski E, O'Hare J, Filatova N, Buettner C. Short term voluntary overfeeding disrupts brain insulin control of adipose tissue lipolysis. J Biol Chem 2012;287:33061-33069
41. Hallschmid M, Benedict C, Schultes B, Born J, Kern W. Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obes 2008;32:275-282
42. Coomans CP, Geerling JJ, Guigas B, et al. Circulating insulin stimulates fatty acid retention in white adipose tissue via KATP channel activation in the central nervous system only in insulin-sensitive mice. J Lipid Res 2011;52:1712-1722
43. Iwen KA, Scherer T, Heni M, et al. Intranasal insulin suppresses systemic but not subcutaneous lipolysis in healthy humans. J Clin Endocrinol Metab 2014;99:E246-E251
44. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008;7:125-134
45. Abe M, Saito M, Shimazu T. Neuropeptide Y in the specific hypothalamic nuclei of rats treated neonatally with monosodium glutamate. Brain Res Bull 1990;24:289-291
46. Lima CB, Soares GdeS, Vitor SM, Castellano B, Andrade da Costa BL, Guedes RC. Neonatal treatment with monosodium glutamate lastingly facilitates spreading depression in the rat cortex. Life Sci 2013;93:388-392
47. Yue JT, Abraham MA, LaPierre MP, et al. A fatty acid-dependent hypothalamic-DVC neurocircuitry that regulates hepatic secretion of triglyceride-rich lipoproteins. Nat Commun 2015;6:5970
48. Banks WA, Jaspan JB, Kastin AJ. Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides 1997;18:1257-1262
49. Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care 2013;36:522-528
50. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147